
Professor David Denning
University of Manchester, Infectious Disease Clinician
Antimicrobial resistance can complicate advanced medical treatment, including cancer care. Explore the consequences for patients and clinicians when effective treatment options are limited.
Initiated and fully funded by Shionogi B.V. Opinions expressed by Prof Denning are his own and in no way influenced by Shionogi.
Patients receiving intensive cancer treatment or other complex medical therapies can be particularly vulnerable to serious infection. It is estimated that around 20% of patients with cancer will require antibiotics during the course of their treatment.1
“Antimicrobials are fundamental to modern cancer care. Research has demonstrated that preventative antibiotic treatment can reduce the relative risk of infection-related death in patients with chemotherapy induced neutropenia by almost 40%2” explains Professor of Infectious Diseases at The University of Manchester, David Denning.
Infection-free patients depend on working treatment
While advances in infection prevention in line with modern medicine have improved survival for high-risk patients, rising antimicrobial resistance (AMR) threatens to undermine progress. “The aim is to keep patients infection free during the most vulnerable periods of treatment, so they can go on to receive potentially curative bone marrow or stem-cell transplants,” continues Denning. “This simply wouldn’t be possible without effective antimicrobials and antifungals.”
The devastating impact of resistance
In patients with cancer, the risk of infection-related mortality is much higher. “Some patients are at greater risk than others, many cancer patients are immunocompromised, and antibiotics are often their only hope of accessing life-saving treatments,” says Denning.
When anti-infection treatments are ineffective, clinicians face increasingly difficult decisions and fewer treatment options. “The risk of using broad-spectrum antibiotics is often balanced with the need to save a life,” says Denning. “With options limited, clinicians are left with very little choice.”
But drugs alone won’t solve the problem; we need rapid, accurate diagnostics to detect fungal and antibiotic resistance and inform appropriate treatment selection
Fungal infections, which seriously complicate care for immunocompromised patients and are more common with broad spectrum antibiotic use, are even more challenging to diagnose and treat. “I have witnessed first-hand the devastating impact of a fungal infection on a teenager whose care was already complicated by serious illness,” says Denning.
Rapid diagnostics and stewardship protect progress
The O’Neill Report, commissioned in 2014 and a recent systematic analysis on the global burden of bacterial AMR, outlines the need for urgent intervention, predicting that rising AMR could cause up to 10 million deaths annually by the year 2050,3,4 which Denning explains could surpass mortality from cancer alone. “We need new antimicrobials,” he says. “But drugs alone won’t solve the problem; we need rapid, accurate diagnostics to detect fungal and antibiotic resistance and inform appropriate treatment selection.”
Advanced hospital-based stewardship programmes, involving infection specialists and pharmacists, ensure antimicrobials are used at the right dose, for the right patient and duration, with appropriate monitoring. Together, these approaches help to avoid unnecessary antibiotic exposure, preserving treatment efficacy, and usually reduce cost as a secondary benefit.
“This is essential to protect patients undergoing advanced cancer and intensive care,” says Denning. “Protecting the few effective antimicrobials we have access to and safeguarding future treatment options is integral to progress.”
Rising resistance can limit the utility of innovation
Despite it being a global public health concern, the development pipeline for new antibiotics remains alarmingly thin, while AMR threatens to undermine advances across medicine. The implications extend far beyond infectious diseases, throughout oncology, transplant medicine, routine surgery, autoimmune disease, critical care and beyond. While bringing new drugs to market is essential, Denning warns this must not be limited to high-income countries. “We need to support the rollout of new drugs and high-performing diagnostics in lower- and middle income countries where many of these resistant infections occur,” he explains. “Limited access to diagnostics, specialist expertise and effective antimicrobials makes managing resistant infections particularly challenging in these settings.”
The need to preserve advances in modern medicine relies on a collaborative approach, with pharmaceutical companies recognising the implications of AMR across their wider therapeutic pipeline and governments committing to sustained investment in research, development and access to new treatments. Novel business models have reduced the barriers to introducing new antimicrobials and should be more widely used.5
[1] Gupta, Vikas et al. “Burden of Antimicrobial Resistance in Adult Hospitalized Patients With Cancer: A Multicenter Analysis.” Cancer medicine vol. 13,24 (2024): e70495. doi:10.1002/cam4.70495.
[2] Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;(1):CD004386.
[3] Review on Antimicrobial Resistance, chaired by Jim O’Neill. 2016. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Review on Antimicrobial Resistance, May 2016. tinyurl.com/29e4nf2t
[4] Naghavi M, Vollset S, Ikuta K et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, 2024; 404, 1199-1226.
[5] Farha, M A. et al. 2025. Important challenges to finding new leads for new antibiotics. Current Opinion in Microbiology, Volume 83. ISSN 1369-5274. doi. org/10.1016/j.mib.2024.102562
NP-EU-NP-0393, November 2026
Global Cause